Global HER2 Tumor Marker Testing Market Research Report 2024

Publication ID:

PB508247986

Publication Date:

August 21, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

HER2 Tumor Marker Testing is a diagnostic test used in oncology to assess the status of the HER2 gene and the presence of HER2 protein receptors in breast cancer and some other types of cancer, such as gastric (stomach) cancer. HER2 stands for Human Epidermal Growth Factor Receptor 2, which is a gene that encodes a protein receptor on the surface of certain cells, including breast cells. HER2 status is an important factor in determining treatment options and predicting the prognosis for individuals with specific types of cancer.
The global HER2 Tumor Marker Testing market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global market for HER2 Tumor Marker Testing has been experiencing steady growth. This growth is primarily driven by the increasing incidence of breast cancer and the importance of HER2 status in determining treatment decisions. The market size is influenced by factors such as population aging, awareness of breast cancer screening, and advancements in diagnostic techniques. North America, particularly the United States, is a significant market for HER2 Tumor Marker Testing. The region has well-established breast cancer screening and diagnosis programs. The adoption of targeted therapies, such as Herceptin, has been prominent in this region. Europe also has a substantial market for HER2 testing, with countries like the United Kingdom, Germany, and France being key contributors. The European market is characterized by a growing emphasis on early cancer detection and personalized medicine. The Asia-Pacific region, including countries like China and India, offers growth opportunities. The increasing healthcare spending, growing awareness of breast cancer, and rising population contribute to market expansion.
This report aims to provide a comprehensive presentation of the global market for HER2 Tumor Marker Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding HER2 Tumor Marker Testing.
Report Scope
The HER2 Tumor Marker Testing market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global HER2 Tumor Marker Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the HER2 Tumor Marker Testing companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Abbott
Roche
Thermo Fisher Scientific
Agilent
Leica Biosystems
Biocare Medical
BioGenex
Sysmex
Abnova
Novartis
InvivoGen
Segment by Type
Immunohistochemistry (IHC)
Fluorescence In Situ Hybridization (FISH)
Silver In Situ Hybridization (SISH)
Others
Segment by Application
Hospitals
Diagnostic Laboratories
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of HER2 Tumor Marker Testing companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global HER2 Tumor Marker Testing Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunohistochemistry (IHC)
1.2.3 Fluorescence In Situ Hybridization (FISH)
1.2.4 Silver In Situ Hybridization (SISH)
1.2.5 Others
1.3 Market by Application
1.3.1 Global HER2 Tumor Marker Testing Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Diagnostic Laboratories
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global HER2 Tumor Marker Testing Market Perspective (2019-2030)
2.2 HER2 Tumor Marker Testing Growth Trends by Region
2.2.1 Global HER2 Tumor Marker Testing Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 HER2 Tumor Marker Testing Historic Market Size by Region (2019-2024)
2.2.3 HER2 Tumor Marker Testing Forecasted Market Size by Region (2025-2030)
2.3 HER2 Tumor Marker Testing Market Dynamics
2.3.1 HER2 Tumor Marker Testing Industry Trends
2.3.2 HER2 Tumor Marker Testing Market Drivers
2.3.3 HER2 Tumor Marker Testing Market Challenges
2.3.4 HER2 Tumor Marker Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top HER2 Tumor Marker Testing Players by Revenue
3.1.1 Global Top HER2 Tumor Marker Testing Players by Revenue (2019-2024)
3.1.2 Global HER2 Tumor Marker Testing Revenue Market Share by Players (2019-2024)
3.2 Global HER2 Tumor Marker Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by HER2 Tumor Marker Testing Revenue
3.4 Global HER2 Tumor Marker Testing Market Concentration Ratio
3.4.1 Global HER2 Tumor Marker Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by HER2 Tumor Marker Testing Revenue in 2023
3.5 HER2 Tumor Marker Testing Key Players Head office and Area Served
3.6 Key Players HER2 Tumor Marker Testing Product Solution and Service
3.7 Date of Enter into HER2 Tumor Marker Testing Market
3.8 Mergers & Acquisitions, Expansion Plans
4 HER2 Tumor Marker Testing Breakdown Data by Type
4.1 Global HER2 Tumor Marker Testing Historic Market Size by Type (2019-2024)
4.2 Global HER2 Tumor Marker Testing Forecasted Market Size by Type (2025-2030)
5 HER2 Tumor Marker Testing Breakdown Data by Application
5.1 Global HER2 Tumor Marker Testing Historic Market Size by Application (2019-2024)
5.2 Global HER2 Tumor Marker Testing Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America HER2 Tumor Marker Testing Market Size (2019-2030)
6.2 North America HER2 Tumor Marker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America HER2 Tumor Marker Testing Market Size by Country (2019-2024)
6.4 North America HER2 Tumor Marker Testing Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe HER2 Tumor Marker Testing Market Size (2019-2030)
7.2 Europe HER2 Tumor Marker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe HER2 Tumor Marker Testing Market Size by Country (2019-2024)
7.4 Europe HER2 Tumor Marker Testing Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific HER2 Tumor Marker Testing Market Size (2019-2030)
8.2 Asia-Pacific HER2 Tumor Marker Testing Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific HER2 Tumor Marker Testing Market Size by Region (2019-2024)
8.4 Asia-Pacific HER2 Tumor Marker Testing Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America HER2 Tumor Marker Testing Market Size (2019-2030)
9.2 Latin America HER2 Tumor Marker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America HER2 Tumor Marker Testing Market Size by Country (2019-2024)
9.4 Latin America HER2 Tumor Marker Testing Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa HER2 Tumor Marker Testing Market Size (2019-2030)
10.2 Middle East & Africa HER2 Tumor Marker Testing Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa HER2 Tumor Marker Testing Market Size by Country (2019-2024)
10.4 Middle East & Africa HER2 Tumor Marker Testing Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott
11.1.1 Abbott Company Detail
11.1.2 Abbott Business Overview
11.1.3 Abbott HER2 Tumor Marker Testing Introduction
11.1.4 Abbott Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.1.5 Abbott Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche HER2 Tumor Marker Testing Introduction
11.2.4 Roche Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Thermo Fisher Scientific
11.3.1 Thermo Fisher Scientific Company Detail
11.3.2 Thermo Fisher Scientific Business Overview
11.3.3 Thermo Fisher Scientific HER2 Tumor Marker Testing Introduction
11.3.4 Thermo Fisher Scientific Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.3.5 Thermo Fisher Scientific Recent Development
11.4 Agilent
11.4.1 Agilent Company Detail
11.4.2 Agilent Business Overview
11.4.3 Agilent HER2 Tumor Marker Testing Introduction
11.4.4 Agilent Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.4.5 Agilent Recent Development
11.5 Leica Biosystems
11.5.1 Leica Biosystems Company Detail
11.5.2 Leica Biosystems Business Overview
11.5.3 Leica Biosystems HER2 Tumor Marker Testing Introduction
11.5.4 Leica Biosystems Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.5.5 Leica Biosystems Recent Development
11.6 Biocare Medical
11.6.1 Biocare Medical Company Detail
11.6.2 Biocare Medical Business Overview
11.6.3 Biocare Medical HER2 Tumor Marker Testing Introduction
11.6.4 Biocare Medical Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.6.5 Biocare Medical Recent Development
11.7 BioGenex
11.7.1 BioGenex Company Detail
11.7.2 BioGenex Business Overview
11.7.3 BioGenex HER2 Tumor Marker Testing Introduction
11.7.4 BioGenex Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.7.5 BioGenex Recent Development
11.8 Sysmex
11.8.1 Sysmex Company Detail
11.8.2 Sysmex Business Overview
11.8.3 Sysmex HER2 Tumor Marker Testing Introduction
11.8.4 Sysmex Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.8.5 Sysmex Recent Development
11.9 Abnova
11.9.1 Abnova Company Detail
11.9.2 Abnova Business Overview
11.9.3 Abnova HER2 Tumor Marker Testing Introduction
11.9.4 Abnova Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.9.5 Abnova Recent Development
11.10 Novartis
11.10.1 Novartis Company Detail
11.10.2 Novartis Business Overview
11.10.3 Novartis HER2 Tumor Marker Testing Introduction
11.10.4 Novartis Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.10.5 Novartis Recent Development
11.11 InvivoGen
11.11.1 InvivoGen Company Detail
11.11.2 InvivoGen Business Overview
11.11.3 InvivoGen HER2 Tumor Marker Testing Introduction
11.11.4 InvivoGen Revenue in HER2 Tumor Marker Testing Business (2019-2024)
11.11.5 InvivoGen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Abbott
Roche
Thermo Fisher Scientific
Agilent
Leica Biosystems
Biocare Medical
BioGenex
Sysmex
Abnova
Novartis
InvivoGen

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂